Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;34(3):243-50.
doi: 10.1016/j.det.2016.02.006.

Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea

Nicole M Fett  1 , David Fiorentino  2 , Victoria P Werth  3
Affiliations
Review

Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea

Nicole M Fett et al. Dermatol Clin. 2016 Jul.

Abstract

Patients with skin-predominant lupus erythematosus, dermatomyositis, and morphea should be evaluated, treated, and followed by dermatologists who can take primary responsibility for their care. Many academic centers have specialized centers with dermatologists who care for these patients. Patients with skin-predominant lupus erythematosus should be followed regularly with laboratory tests to detect significant systemic disease. Antibody tests can help determine the risks for individual patients. Patients with morphea rarely progress to systemic disease, but therapies can be helpful in treating and preventing progression of disease.

Keywords: Dermatomyositis; Educational gaps; Lupus; Morphea; Practice.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Alopecias in lupus erythematosus.
    Concha JSS, Werth VP. Concha JSS, et al. Lupus Sci Med. 2018 Oct 25;5(1):e000291. doi: 10.1136/lupus-2018-000291. eCollection 2018. Lupus Sci Med. 2018. PMID: 30397497 Free PMC article.
  • Dermatomyositis sine myositis - Case presentation.
    Kaltsonoudis E, Pelechas E, Drosos AA. Kaltsonoudis E, et al. Mediterr J Rheumatol. 2017 Mar 28;28(1):57-58. doi: 10.31138/mjr.28.1.57. eCollection 2017 Mar. Mediterr J Rheumatol. 2017. PMID: 32185256 Free PMC article.

References

    1. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J. Invest. Dermatol. 2005;125:889–894. - PMC - PubMed
    1. Browning DJ. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–428. e1. - PubMed
    1. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med. 1991;324:150–154. - PubMed
    1. Mosca M, Tani C, Aringer M, et al. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269–1274. - PMC - PubMed
    1. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391–404. - PMC - PubMed

MeSH terms